LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 223

Search options

  1. Article ; Online: Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development.

    Wei, Qian / Taskén, Kjetil

    The Biochemical journal

    2022  Volume 479, Issue 20, Page(s) 2219–2260

    Abstract: Through activation of immune cells, the immune system is responsible for identifying and destroying infected or otherwise damaged cells including tumorigenic cells that can be recognized as foreign, thus maintaining homeostasis. However, tumor cells have ...

    Abstract Through activation of immune cells, the immune system is responsible for identifying and destroying infected or otherwise damaged cells including tumorigenic cells that can be recognized as foreign, thus maintaining homeostasis. However, tumor cells have evolved several mechanisms to avoid immune cell detection and killing, resulting in tumor growth and progression. In the tumor microenvironment, tumor infiltrating immune cells are inactivated by soluble factors or tumor promoting conditions and lose their effects on tumor cells. Analysis of signaling and crosstalk between immune cells and tumor cells have helped us to understand in more detail the mechanisms of tumor immune evasion and this forms basis for drug development strategies in the area of cancer immunotherapy. In this review, we will summarize the dominant signaling networks involved in immune escape and describe the status of development of therapeutic strategies to target tumor immune evasion mechanisms with focus on how the tumor microenvironment interacts with T cells.
    MeSH term(s) Humans ; Tumor Escape ; Tumor Microenvironment ; Immunotherapy/methods ; Neoplasms/drug therapy ; T-Lymphocytes ; Immune Evasion
    Language English
    Publishing date 2022-10-28
    Publishing country England
    Document type Review ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2969-5
    ISSN 1470-8728 ; 0006-2936 ; 0306-3275 ; 0264-6021
    ISSN (online) 1470-8728
    ISSN 0006-2936 ; 0306-3275 ; 0264-6021
    DOI 10.1042/BCJ20210233
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Small molecule inhibitors targeting regulatory T cells for cancer treatment.

    García-Díaz, Nuria / Wei, Qian / Taskén, Kjetil

    European journal of immunology

    2023  Volume 54, Issue 2, Page(s) e2350448

    Abstract: Regulatory T cells (Tregs) are important controllers of the immune system homeostasis by preventing disproportionate immune responses. In the context of cancer, Tregs contribute to tumor development by suppressing other immune cells in the tumor ... ...

    Abstract Regulatory T cells (Tregs) are important controllers of the immune system homeostasis by preventing disproportionate immune responses. In the context of cancer, Tregs contribute to tumor development by suppressing other immune cells in the tumor microenvironment (TME). Infiltration of Tregs in the TME has been associated with poor prognosis in cancer patients. Thus, understanding the mechanisms underlying Treg recruitment and suppressive functions is essential for developing cancer immunotherapies to boost antitumor immune responses. While antibody-based strategies targeting Tregs have shown promise, small molecule inhibitors offer distinct advantages, including oral bioavailability and the ability to penetrate the TME and target intracellular proteins. Here, we provide an overview of small molecule inhibitors that have demonstrated efficacy in modulating Tregs activity in cancer and highlight the need for phenotypic assays to characterize therapeutic compounds.
    MeSH term(s) Humans ; T-Lymphocytes, Regulatory ; Neoplasms/drug therapy ; Neoplasms/pathology ; Immunotherapy ; Tumor Microenvironment
    Language English
    Publishing date 2023-11-15
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 120108-6
    ISSN 1521-4141 ; 0014-2980
    ISSN (online) 1521-4141
    ISSN 0014-2980
    DOI 10.1002/eji.202350448
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Phosphoproteomics-Based Characterization of Prostaglandin E

    Lone, Anna Mari / Taskén, Kjetil

    Molecular pharmacology

    2021  Volume 99, Issue 5, Page(s) 370–382

    Abstract: Prostaglandin ... ...

    Abstract Prostaglandin E
    MeSH term(s) Dinoprostone/metabolism ; Humans ; Phosphorylation/physiology ; Proteome/metabolism ; Proteomics/methods ; Signal Transduction/physiology ; T-Lymphocytes/metabolism
    Chemical Substances Proteome ; Dinoprostone (K7Q1JQR04M)
    Language English
    Publishing date 2021-03-04
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 124034-1
    ISSN 1521-0111 ; 0026-895X
    ISSN (online) 1521-0111
    ISSN 0026-895X
    DOI 10.1124/molpharm.120.000170
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Carboxyl-Terminal Src Kinase Binds CD28 upon Activation and Mutes Downstream Signaling.

    Skånland, Sigrid S / Taskén, Kjetil

    Journal of immunology (Baltimore, Md. : 1950)

    2019  Volume 203, Issue 4, Page(s) 1055–1063

    Abstract: Full T cell activation depends on stimulation of the TCR in conjunction with a costimulatory receptor. The involvement of costimulatory molecules is potent, and a mechanistic understanding of how downstream signaling is regulated is required to fully ... ...

    Abstract Full T cell activation depends on stimulation of the TCR in conjunction with a costimulatory receptor. The involvement of costimulatory molecules is potent, and a mechanistic understanding of how downstream signaling is regulated is required to fully understand T cell responsiveness. In this study, a proteomic approach was taken to identify the interactomes of the coreceptors CD2 and CD28. These coreceptors are both positive regulators of T cell activation, but CD28 less potently induces TCR-proximal signaling. C-terminal Src kinase (CSK), a negative regulator of TCR signaling, was identified as a specific and direct interactor only of activated CD28. CSK is recruited to CD28 upon T cell activation, and the in vitro kinase activity of CSK is enhanced in the presence of phosphorylated CD28. Interruption of the CSK/CD28 interaction prior to TCR/CD28 costimulation induces a signaling response which mimics the more potent CD2-induced TCR-proximal pathway activation. Thus, CD28 functions as a novel adaptor protein for CSK, and CSK regulates signaling downstream of CD28.
    MeSH term(s) CD28 Antigens/immunology ; CD28 Antigens/metabolism ; CSK Tyrosine-Protein Kinase/immunology ; CSK Tyrosine-Protein Kinase/metabolism ; Cells, Cultured ; Humans ; Lymphocyte Activation/immunology ; Signal Transduction/immunology ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism
    Chemical Substances CD28 Antigens ; CSK Tyrosine-Protein Kinase (EC 2.7.10.2) ; CSK protein, human (EC 2.7.10.23)
    Language English
    Publishing date 2019-07-10
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 3056-9
    ISSN 1550-6606 ; 0022-1767 ; 1048-3233 ; 1047-7381
    ISSN (online) 1550-6606
    ISSN 0022-1767 ; 1048-3233 ; 1047-7381
    DOI 10.4049/jimmunol.1801660
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models.

    Flobak, Åsmund / Skånland, Sigrid S / Hovig, Eivind / Taskén, Kjetil / Russnes, Hege G

    Trends in pharmacological sciences

    2022  Volume 43, Issue 11, Page(s) 973–985

    Abstract: Functional precision medicine is a new, emerging area that can guide cancer treatment by capturing information from direct perturbations of tumor-derived, living cells, such as by drug sensitivity screening. Precision cancer medicine as currently ... ...

    Abstract Functional precision medicine is a new, emerging area that can guide cancer treatment by capturing information from direct perturbations of tumor-derived, living cells, such as by drug sensitivity screening. Precision cancer medicine as currently implemented in clinical practice has been driven by genomics, and current molecular tumor boards rely extensively on genomic characterization to advise on therapeutic interventions. However, genomic biomarkers can only guide treatment decisions for a fraction of the patients. In this review we provide an overview of the current state of functional precision medicine, highlight advances for drug-sensitivity screening enabled by cell culture models, and discuss how artificial intelligence (AI) can be coupled to functional precision medicine to guide patient stratification.
    MeSH term(s) Artificial Intelligence ; Biomarkers, Tumor ; Cell Culture Techniques ; Early Detection of Cancer ; Humans ; Neoplasms/drug therapy ; Precision Medicine
    Chemical Substances Biomarkers, Tumor
    Language English
    Publishing date 2022-09-23
    Publishing country England
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 282846-7
    ISSN 1873-3735 ; 0165-6147
    ISSN (online) 1873-3735
    ISSN 0165-6147
    DOI 10.1016/j.tips.2022.08.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Waking up regulatory T cells.

    Taskén, Kjetil

    Blood

    2009  Volume 114, Issue 6, Page(s) 1136–1137

    Language English
    Publishing date 2009-08-06
    Publishing country United States
    Document type Comment ; Journal Article
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood-2009-06-223222
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: B cell signalling pathways-New targets for precision medicine in chronic lymphocytic leukaemia.

    Skånland, Sigrid S / Karlsen, Linda / Taskén, Kjetil

    Scandinavian journal of immunology

    2020  Volume 92, Issue 5, Page(s) e12931

    Abstract: The B cell receptor (BCR) is a master regulator of B cells, controlling cellular processes such as proliferation, migration and survival. Cell signalling downstream of the BCR is aberrantly activated in the B cell malignancy chronic lymphocytic leukaemia ...

    Abstract The B cell receptor (BCR) is a master regulator of B cells, controlling cellular processes such as proliferation, migration and survival. Cell signalling downstream of the BCR is aberrantly activated in the B cell malignancy chronic lymphocytic leukaemia (CLL), supporting the pathophysiology of the disease. This insight has led to development and approval of small molecule inhibitors that target components of the BCR pathway. These advances have greatly improved the management of CLL, but the disease remains incurable. This may partly be explained by the inter-patient heterogeneity of the disease, also when it comes to treatment responses. Precision medicine is therefore required to optimize treatment and move towards a cure. Here, we discuss how the introduction of BCR signalling inhibitors has facilitated the development of functional in vitro assays to guide clinical treatment decisions on use of the same therapeutic agents in individual patients. The cellular responses to these agents can be analysed in high-throughput assays such as dynamic BH3 profiling, phospho flow experiments and drug sensitivity screens to identify predictive biomarkers. This progress exemplifies the positive synergy between basal and translational research needed to optimize patient care.
    MeSH term(s) Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors ; Agammaglobulinaemia Tyrosine Kinase/immunology ; Agammaglobulinaemia Tyrosine Kinase/metabolism ; B-Lymphocytes/immunology ; B-Lymphocytes/metabolism ; Class Ib Phosphatidylinositol 3-Kinase/immunology ; Class Ib Phosphatidylinositol 3-Kinase/metabolism ; Enzyme Inhibitors/therapeutic use ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/immunology ; Leukemia, Lymphocytic, Chronic, B-Cell/metabolism ; Molecular Targeted Therapy/methods ; Precision Medicine/methods ; Receptors, Antigen, B-Cell/antagonists & inhibitors ; Receptors, Antigen, B-Cell/immunology ; Receptors, Antigen, B-Cell/metabolism ; Signal Transduction/drug effects ; Signal Transduction/immunology
    Chemical Substances Enzyme Inhibitors ; Receptors, Antigen, B-Cell ; Class Ib Phosphatidylinositol 3-Kinase (EC 2.7.1.137) ; PIK3CG protein, human (EC 2.7.1.137) ; Agammaglobulinaemia Tyrosine Kinase (EC 2.7.10.2) ; BTK protein, human (EC 2.7.10.2)
    Language English
    Publishing date 2020-10-10
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 120476-2
    ISSN 1365-3083 ; 0300-9475
    ISSN (online) 1365-3083
    ISSN 0300-9475
    DOI 10.1111/sji.12931
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Evolutionary mode and timing of dissemination of high-grade serous carcinomas.

    Sveen, Anita / Johannessen, Bjarne / Klokkerud, Solveig Mk / Kraggerud, Sigrid M / Meza-Zepeda, Leonardo A / Bjørnslett, Merete / Bischof, Katharina / Myklebost, Ola / Taskén, Kjetil / Skotheim, Rolf I / Dørum, Anne / Davidson, Ben / Lothe, Ragnhild A

    JCI insight

    2024  Volume 9, Issue 3

    Abstract: Dissemination within the peritoneal cavity is a main determinant of poor patient outcomes from high-grade serous carcinomas (HGSCs). The dissemination process is poorly understood from a cancer evolutionary perspective. We reconstructed the evolutionary ... ...

    Abstract Dissemination within the peritoneal cavity is a main determinant of poor patient outcomes from high-grade serous carcinomas (HGSCs). The dissemination process is poorly understood from a cancer evolutionary perspective. We reconstructed the evolutionary trajectories across a median of 5 tumor sites and regions from each of 23 patients based on deep whole-exome sequencing. Polyclonal cancer origin was detected in 1 patient. Ovarian tumors had more complex subclonal architectures than other intraperitoneal tumors in each patient, which indicated that tumors developed earlier in the ovaries. Three common modes of dissemination were identified, including monoclonal or polyclonal dissemination of monophyletic (linear) or polyphyletic (branched) subclones. Mutation profiles of initial or disseminated clones varied greatly among cancers, but recurrent mutations were found in 7 cancer-critical genes, including TP53, BRCA1, BRCA2, and DNMT3A, and in the PI3K/AKT1 pathway. Disseminated clones developed late in the evolutionary trajectory models of most cancers, in particular in cancers with DNA damage repair deficiency. Polyclonal dissemination was predicted to occur predominantly as a single and rapid wave, but chemotherapy exposure was associated with higher genomic diversity of disseminated clones. In conclusion, we described three common evolutionary dissemination modes across HGSCs and proposed factors associated with dissemination diversity.
    MeSH term(s) Female ; Humans ; Mutation ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/pathology ; Carcinoma
    Language English
    Publishing date 2024-01-04
    Publishing country United States
    Document type Journal Article
    ISSN 2379-3708
    ISSN (online) 2379-3708
    DOI 10.1172/jci.insight.170423
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Correction for Bjørgo et al., "Cross Talk between Phosphatidylinositol 3-Kinase and Cyclic AMP (cAMP)-Protein Kinase A Signaling Pathways at the Level of a Protein Kinase B/β-Arrestin/cAMP Phosphodiesterase 4 Complex".

    Bjørgo, Elisa / Solheim, Silje A / Abrahamsen, Hilde / Baillie, George S / Brown, Kim M / Berge, Torunn / Okkenhaug, Klaus / Houslay, Miles D / Taskén, Kjetil

    Molecular and cellular biology

    2022  Volume 42, Issue 2, Page(s) e0055621

    Language English
    Publishing date 2022-02-17
    Publishing country United States
    Document type Journal Article ; Published Erratum
    ZDB-ID 779397-2
    ISSN 1098-5549 ; 0270-7306
    ISSN (online) 1098-5549
    ISSN 0270-7306
    DOI 10.1128/mcb.00556-21
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: The Presence of Activated T Cell Subsets prior to Transplantation Is Associated with Increased Rejection Risk in Pancreas Transplant Recipients.

    Chellappa, Stalin / Kushekhar, Kushi / Hagness, Morten / Horneland, Rune / Taskén, Kjetil / Aandahl, Einar Martin

    Journal of immunology (Baltimore, Md. : 1950)

    2021  Volume 207, Issue 10, Page(s) 2501–2511

    Abstract: Pancreas and islet transplantation (PTx) are currently the only curative treatment options for type 1 diabetes. ... ...

    Abstract Pancreas and islet transplantation (PTx) are currently the only curative treatment options for type 1 diabetes. CD4
    MeSH term(s) Adult ; Female ; Graft Rejection/immunology ; Humans ; Lymphocyte Activation/immunology ; Male ; Middle Aged ; Pancreas Transplantation/adverse effects ; T-Lymphocyte Subsets/immunology ; Transplantation Immunology/immunology
    Language English
    Publishing date 2021-10-04
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 3056-9
    ISSN 1550-6606 ; 0022-1767 ; 1048-3233 ; 1047-7381
    ISSN (online) 1550-6606
    ISSN 0022-1767 ; 1048-3233 ; 1047-7381
    DOI 10.4049/jimmunol.2001103
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top